ChromaCode – Innovative Molecular Diagnostics
Mark McDonough, CEO of ChromaCode, a molecular diagnostics company, discusses how ChromaCode technology provides a cost-effective, rapid, and accurate method of testing clinically actionable biomarkers. He also talks about the partnership with MedGenome to bring affordable diagnostics to India and the middle east.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Healthcare. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Healthcare and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Healthcare?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Key Takeaways
- Key Point: Mark McDonough, CEO of ChromaCode, a molecular diagnostics company, discusses how ChromaCode technology provides a cost-effective, rapid, and accurate method of testing clin…
- Key Point: He also talks about the partnership with MedGenome to bring affordable diagnostics to India and the middle east.
- Key Point: Mark has over 25 years of experience helping build high growth HealthCare organizations.
- Key Point: He is passionate about his team, his customers, and the patients that he and they are privileged to help serve.
- Key Point: He most recently was the CEO of Pierian (now Velsera) which he led to a successful sale to Summa Equity, a private equity firm, in 2022.
Mark has over 25 years of experience helping build high growth HealthCare organizations. He is passionate about his team, his customers, and the patients that he and they are privileged to help serve. He most recently was the CEO of Pierian (now Velsera) which he led to a successful sale to Summa Equity, a private equity firm, in 2022. Prior to Pierian, he led CombiMatrix for five years, culminating in a sale to Invitae in 2017. Over his career, Mark has held various executive and commercial positions, and served as a US Naval Officer.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.



